

## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

	<b>1 Volume</b>
<b>MODULE 1 ADMINISTRATIVE INFORMATION AND PRESCRIBING INFORMATION</b>	<b>1</b>
<b>1.0 LETTER OF APPLICATION</b>	<b>1</b>
<b>1.1 COMPREHENSIVE TABLE OF CONTENTS</b>	<b>1</b>
<b>1.2 APPLICATION FORM</b>	<b>1</b>
<b>1.2.1 Application Form</b>	<b>1</b>
<b>1.2.2 Annexes to the application form</b>	<b>1</b>
1.2.2.1 Proof of payment	1
1.2.2.2 Letter of authorisation for communication on behalf of the applicant/PHCR	1
1.2.2.3 Dossier product batch information	1
1.2.2.4 Electronic copy declaration	1
1.2.2.5 Curriculum vitae of the qualified person for pharmacovigilance	1
1.2.2.6 Copy of written confirmation from the manufacturer of the API to inform the applicant in case of modification of the manufacturing process or specifications.	1
<b>1.3 SOUTH AFRICAN LABELLING AND PACKAGING</b>	<b>1</b>
1.3.1 Proposed South African Package Insert	1
1.3.2 Proposed South African Patient Information Leaflet	1
1.3.3 Label & Carton	1
<b>1.4 INFORMATION ABOUT THE EXPERTS</b>	<b>1</b>
<b>1.4.1 Quality</b>	<b>1</b>
U10-1556-01 Information about the Expert - Quality	1
<b>1.4.2 Non-Clinical</b>	<b>1</b>
U10-1874-01 Information about the Expert - Non-Clinical	1
<b>1.4.3 Clinical</b>	<b>1</b>
U10-1864-01 Information about the Expert - Clinical	1
<b>1.5 N/A for this submission</b>	<b>N/A</b>
<b>1.6 N/A for this submission</b>	<b>N/A</b>
<b>1.7 GOOD MANUFACTURING PRACTICE</b>	<b>1</b>
<b>1.7.1 Date of last inspection of each manufacturing site</b>	<b>1</b>
<b>1.7.2 Confirmation of inspections performed by the FDA and confirmation of Drug Firm Registration by the FDA.</b>	<b>1</b>

## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

1.7.3	Certificate of GMP Compliance for yyyyy and copies of Manufacturing Licences for South African Companies.	1
1.7.4	Local Release	1
1.7.4.1	Finished Product Release Control (FPRC) tests	1
1.7.4.2	Finished Product Release Responsibility (FPRR) criteria	1
1.7.5	Confirmation of contract between xxxxx and ZZZZZ	1
1.7.6	Certificate of a Pharmaceutical Product/ Marketing authorisation certificate for the product	N/A
1.7.7	Proof of current registration of the Responsible Pharmacist by the SAPC in terms of Act 53 (Pharmacy Act)	1
1.7.8	Proof of current registration by the SAPC in terms of Act 53 (Pharmacy Act) of the pharmacist signing the dossier.	1
1.7.9	Proof (copy of the certificate) of registration of the Ingelheim Pharmaceuticals (Pty) Ltd as a pharmacy	1
1.7.10	Sample and Documents	1
1.7.10.1	Confirmation of submission of a sample.	1
1.7.10.2	Availability of executed batch manufacturing and packaging documents.	1
1.7.10.3	Certificate of Analyses of sample batch and Certificate of Analyses of active ingredient.	1
1.7.11	Master documentation available for inspection	1
1.7.12	Certified copy of a permit to manufacture specified Schedule 5, Schedules 6, 7 and 8 substances	N/A
1.7.13	Inspection flow diagram	1
1.8	<b>DETAILS OF COMPLIANCE WITH SCREENING OUTCOMES</b>	1
1.9	<b>INDIVIDUAL PATIENT DATA - STATEMENT OF AVAILABILITY</b>	1
1.10	<b>FOREIGN REGULATORY STATUS</b>	1
1.10.1	List of countries where AVATAR has been submitted	1
1.10.2	Registration certificates or marketing authorisation	N/A
1.10.3	Foreign prescribing and patient information	N/A
1.10.4	Data set similarities	1
1.10.5	Statement on application rejection, withdrawal or repeated deferral	N/A
1.10.6	Reason for non-registration in country of origin	N/A
1.11	<b>BIOEQUIVALENCE TRIAL INFORMATION</b>	1
1.12	<b>PAEDIATRIC DEVELOPMENT PROGRAM</b>	1
	Official Decision Agreed PIP Deferral/Waiver	1

## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

<b>MODULE 2</b>	<b>CTD SUMMARIES</b>	<b>5 Volumes</b>
2.1	CTD TABLE OF CONTENTS (MODULE 2 - 5)	1
2.2	INTRODUCTION	1
2.3	QUALITY OVERALL SUMMARY (U10-1867-01)	1
2.4	NONCLINIAL OVERVIEW (U10-1874-01)	1
2.5	CLINICAL OVERVIEW (U10-1906-01)	1
2.6	NONCLINICAL WRITTEN AND TABULATED SUMMARIES (U10-1873-01)	1
2.6.1	Introduction	1
2.6.2	Pharmacology Written Summary	1
2.6.3	Pharmacology Tabulated Summary	1
2.6.4	Pharmacokinetics Written Summary	1
2.6.5	Pharmacokinetics Tabulated Summary	1
2.6.6	Toxicology Written Summary	2
2.6.7	Toxicology Tabulated Summary	2
2.7	CLINICAL SUMMARY (U10-1864-01)	2
2.7.1	Summary of Biopharmaceutics and Associated Analytical Methods	2
2.7.2	Summary of Clinical Pharmacology Studies	3
2.7.3	Summary of Clinical Efficacy	3
2.7.4	Summary of Clinical Safety	4
2.7.5	Literature References	5
2.7.6	Synopses of Individual Studies	5

## 1.1 COMPREHENSIVE TABLE OF CONTENTS

---

		5 Volumes
<b>MODULE 3</b>	<b>QUALITY</b>	1
<b>3.1</b>	<b>TABLE OF CONTENTS OF MODULE 3</b>	1
<b>3.2</b>	<b>BODY OF DATA</b>	1
<b>3.2.S</b>	<b>ACTIVE PHARMACEUTICAL INGREDIENT</b>	1
<b>3.2.S.1</b>	<b>GENERAL INFORMATION</b>	1
<b>3.2.S.1.1</b>	<b>Nomenclature</b>	1
A107156	Nomenclature Aspirin	1
<b>3.2.S.1.2</b>	<b>Structure</b>	1
A107158	Structure Aspirin	1
<b>3.2.S.1.3</b>	<b>General Properties</b>	1
A107160	General Properties Aspirin	1
<b>3.2.S.2</b>	<b>MANUFACTURE</b>	1
<b>3.2.S.2.1</b>	<b>Manufacturer</b>	1
A107162	Manufacturer Aspirin	1
<b>3.2.S.2.2</b>	<b>Description of Manufacturing Process and Process Controls</b>	1
A097479	Description of Manufacturing Process and Process Controls Aspirin	1
<b>3.2.S.2.3</b>	<b>Control of Materials – N/A (for biological)</b>	
<b>3.2.S.2.4</b>	<b>Controls of Critical Steps and Intermediates</b>	1
A114305	Justification of Controls of Critical Steps Aspirin	1
A117216	Specification (CD 616 BS)	1
A117222	Analytical Procedure Organic Impurities Liquid chromatography	1
A109616	Analytical Procedure Loss on drying Weighing	1
A109617	Analytical Procedure Sulphated ash Weighing	1
A117218	Specification (CD 749 BS)	1
A117223	Analytical Procedure Organic Impurities Liquid chromatography	1
A117220	Specification BS raw	1
A117224	Analytical Procedure Organic Impurities Liquid chromatography	1

## 1.1 COMPREHENSIVE TABLE OF CONTENTS

---

A116645	Specification BS unmilled	1
A101642	Analytical procedure Appearance Visual test	1
A116649	Analytical procedure Organic Impurities Liquid chromatography	1
A116650	Analytical procedure Loss on drying Thermogravimetry	1
<b>3.2.S.2.5</b>	<b>Process Validation and/or Evaluation</b>	N/A
<b>3.2.S.2.6</b>	<b>Manufacturing Process Development</b>	1
A104057	Manufacturing Process Development Aspirin	1
<b>3.2.S.3</b>	<b>CHARACTERISATION</b>	1
<b>3.2.S.3.1</b>	<b>Elucidation of Structure and Other Characteristics</b>	1
U09-1738-01	Elucidation of Structure Aspirin	1
U07-1712-03	Elucidation of Structure Determination of the absolute configuration of a tetrahydrate form of the hydrochloride of the drug substance Aspirin	1
U09-1908-01	Physicochemical Characteristics Aspirin	1
U08-1225-02	Solid-State Forms Aspirin	1
<b>3.2.S.3.2</b>	<b>Impurities</b>	1
U09-2423-01	Impurities Aspirin	1
<b>3.2.S.4</b>	<b>CONTROL OF ACTIVE PHARMACEUTICAL INGREDIENT</b>	2
<b>3.2.S.4.1</b>	<b>Specification</b>	2
A111041	Specification Aspirin	2
<b>3.2.S.4.2</b>	<b>Analytical Procedures</b>	2
A111043	Analytical Procedure IR spectrum IR spectrophotometry (ATR)	2
A111044	Analytical Procedure IR spectrum IR spectrophotometry (KBr)	2
A111045	Analytical Procedure Identification (chiral HPLC) Enantiomeric Purity Liquid chromatography	2
A111046	Analytical Procedure Melting temperature Differential scanning calorimetry	2
A111047	Analytical Procedure Organic impurities Liquid chromatography	2

## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

A111048	Analytical Procedure Organic volatile impurities Gas chromatography	2
A111049	Analytical Procedure Residual solvents Gas chromatography	2
A111050	Analytical Procedure Water content Biamperometric Karl Fischer titration	2
A111051	Analytical Procedure Sulphated ash Weighing	2
A111052	Analytical Procedure Assay (HPLC) Liquid chromatography	2
A111053	Analytical Procedure Particle size Laser-beam diffraction	2
<b>3.2.S.4.3</b>	<b>Validation of Analytical Procedures</b>	2
U09-2573-01	Validation of Analytical Procedure Validation of the Analytical Procedure for the Determination of the Enantiomer BI 1355 by Chiral High Performance Liquid Chromatography	2
U09-2575-01	Validation of Analytical Procedure Validation of Analytical Procedure for the Determination of Organic Impurities in the Drug Substance	2
U09-2571-01	Validation of Analytical Procedure Validation of the Analytical Procedure for the Determination of Organic Volatile Impurities in the Drug Substance	2
U09-2572-01	Validation of Analytical Procedure Validation of the Analytical Procedure for the Determination of Residual Solvents in the Drug Substance	2
U09-2574-01	Validation of Analytical Procedure Validation of the Analytical Procedure for the Assay of the Drug Substance by HPLC	2
A104366	Validation of Analytical Procedure Validation of the Analytical Procedure for Determination of the Particle Size Distribution of the Drug Substance by Laser Diffraction	2
<b>3.2.S.4.4</b>	<b>Batch Analyses</b>	2
U09-2560-01	Batch Analyses Aspirin	2
Annexure 1	Valid Certificates of Analyses (2 batches)	2
<b>3.2.S.4.5</b>	<b>Justification of Specification</b>	2
U09-2552-01	Justification of Specification Aspirin	2
<b>3.2.S.5</b>	<b>REFERENCE STANDARDS</b>	2
U09-2291-01	Reference Standard Aspirin	2
U09-2293-01	Reference Standard BI 1355 BS	2
U09-2326-01	Reference Standard 3-Aminopiperidine Diacetate	2

## 1.1 COMPREHENSIVE TABLE OF CONTENTS

---

U09-2323-01	Reference Standard Ethanolamine	2
<b>3.2.S.6</b>	<b>CONTAINER CLOSURE SYSTEM</b>	<b>2</b>
A107070	Description of the Container Closure System Polyethylene bag / fibre drum	2
<b>3.2.S.7</b>	<b>STABILITY</b>	<b>3</b>
<b>3.2.S.7.1</b>	<b>Stability Summary and Conclusions</b>	<b>3</b>
U09-2559-01	Stability Summary and Conclusions Aspirin	3
<b>3.2.S.7.2</b>	<b>Post-approval Stability Protocol and Stability Commitment</b>	<b>3</b>
H020073	Post-Approval Stability Protocol and Stability Commitment Aspirin	3
<b>3.2.S.7.3</b>	<b>Stability Data</b>	<b>3</b>
U09-2355-01	Stress Stability Data Aspirin	3
U09-2565-01	Accelerated and Long-Term Stability Data for the Aspirin Drug Substance - Primary Stability Results	3
<b>3.2.P.</b>	<b>PHARMACEUTICAL PRODUCT</b>	<b>3</b>
<b>3.2.P.1</b>	<b>DESCRIPTION AND COMPOSITION OF THE PHARMACEUTICAL PRODUCT</b>	<b>3</b>
A110995	Description and Composition of the Pharmaceutical Product Aspirin Film-coated Tablets, 5 mg	3
<b>3.2.P.2</b>	<b>PHARMACEUTICAL DEVELOPMENT</b>	<b>3</b>
U10-1596-01	Pharmaceutical Development Aspirin Film-coated Tablets	3
U10-1396-01	Comparative Dissolution Profile Testing xyz tablets from different origins, overencapsulated and non-encapsulated	3
U10-1606-01	Clinical Trial Formulations and Batches Aspirin Film-coated Tablets	3
<b>3.2.P.3</b>	<b>MANUFACTURE</b>	<b>3</b>
<b>3.2.P.3.1</b>	<b>Manufacturer(s)</b>	<b>3</b>
H020060	Manufacturer Aspirin Film-coated Tablets	3
<b>3.2.P.3.2</b>	<b>Batch Formula</b>	<b>3</b>
A116361	Batch Formula, Aspirin Film-coated Tablets, 5 mg	3
<b>3.2.P.3.3</b>	<b>Description of Manufacturing Process and Process Controls</b>	<b>3</b>
A116363	Description of Manufacturing Process and Process Controls Aspirin Film-coated Tablets, 5 mg	3
A116273	Packaging Procedure Aspirin Film-coated Tablets	3
Annexure 1	Availability of Batch Record for Inspection	3
Annexure 2	Inspection Flow Diagram	3
<b>3.2.P.3.4</b>	<b>Controls of Critical Steps and Intermediates</b>	<b>3</b>

## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

A116365	Justification of Controls at Critical Steps Aspirin Film-coated Tablets, 5 mg	3
<b>3.2.P.3.5</b>	<b>Process Validation and/or Evaluation</b>	<b>3</b>
A113491	Process Validation Aspirin Film-coated Tablets, 5 mg	3
<b>3.2.P.4</b>	<b>CONTROL OF INACTIVE PHARMACEUTICAL INGREDIENTS</b>	<b>3</b>
<b>3.2.P.4.1</b>	<b>Specifications</b>	<b>3</b>
A103215	Specification Aspirin Film-coated Tablets Compendial Excipients	3
A116911	Specification Helium Pink	3
Annexure 1	Product Regulatory Datasheet, confirming compliance with EU directives	3
Annexure 2	Statement confirming that identification of the API will be performed.	3
Annexure 3	Motivation for assay of API not to be performed by manufacturer.	3
Annexure 4	Statement confirming that identification of IPI's are performed by manufacturer.	3
Annexure 5	Frequency of tests performed on water.	3
<b>3.2.P.4.2</b>	<b>Analytical Procedures</b>	<b>3</b>
A090868	Analytical Procedure for Excipient Helium Identification	3
A116907	Analytical Procedure Helium Pink Identification B (IR)	3
A090869	Analytical Procedure for Excipient Residue on Ignition	3
<b>3.2.P.4.4</b>	<b>Justification of Specifications</b>	<b>3</b>
	Certificate of Analysis for Helium pink	3
<b>3.2.P.4.5</b>	<b>Excipients of Human or Animal Origin</b>	<b>3</b>
A116204	Excipients of Human or Animal Origin Aspirin Film-coated Tablets	3
<b>3.2.P.5</b>	<b>CONTROL OF PHARMACEUTICAL PRODUCT</b>	<b>4</b>
<b>3.2.P.5.1</b>	<b>Specification(s)</b>	<b>4</b>
A090869	Specification Aspirin Film-coated Tablets, 5 mg	4
Annexure 1	List of specifications performed for batch release and stability. Refer to 3.2.P.3.3 for in-process controls.	
Annexure 2	Final Release Criteria	
<b>3.2.P.5.2</b>	<b>Analytical Procedures</b>	<b>4</b>
A114646	Analytical Procedure Aspirin Film-coated Tablets Assay, Degradation Products, and Identification	4
A114648	Analytical Procedure Aspirin Film-coated Tablets Loss on Drying	4



## **1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

A114650	Analytical Procedure Aspirin Film-coated Tablets Dissolution	4
A114652	Analytical Procedure Aspirin Film-coated Tablets Uniformity of Dosage Units	4
A114654	Analytical Procedure Aspirin Film-coated Tablets, 5 mg Uniformity of Dosage Units (by NIR)	4
<b>3.2.P.5.3</b>	<b>Validation of Analytical Procedures</b>	<b>4</b>
U10-1408-01	Validation of Analytical Procedure Aspirin Film-coated Tablets, 5 mg Identification, Assay, Degradation products	4
U10-1402-01	Validation of Analytical Procedure Aspirin Film-coated Tablets, 5 mg Dissolution	4
U10-1410-01	Validation of Analytical Procedure Aspirin Film-coated Tablets, 5 mg Content Uniformity	4
A114711	Validation of Analytical Procedure Validation of the Near-Infrared Spectroscopic Method for the Uniformity of Dosage Units of Aspirin Film-coated Tablets, 5 mg	4
<b>3.2.P.5.4</b>	<b>Batch Analyses</b>	<b>4</b>
U10-1235-01	Batch Analyses Aspirin Film-coated Tablets, 5 mg	4
<b>3.2.P.5.5</b>	<b>Characterisation of Impurities</b>	<b>4</b>
U10-1329-01	Impurities Aspirin Film-coated Tablets	4
<b>3.2.P.5.6.</b>	<b>Justification of Specification(s)</b>	<b>4</b>
U10-1397-01	Justification of Specification Aspirin Film-coated Tablets	4
U10-1412-01	Justification of Dissolution Specification Aspirin Film-coated Tablets	4
<b>3.2.P.6</b>	<b>REFERENCE STANDARDS</b>	<b>5</b>
U09-2314-01	Reference Standard CD XX	5
<b>3.2.P.7</b>	<b>CONTAINER CLOSURE SYSTEM</b>	<b>5</b>
A104596	Description of the Container Closure System Aluminium/Aluminium Push-Through Blister	5
A104602	Specification Foil Cold Form Certificate of Analysis for aluminium bottom foil	5
A116004	Specification Aluminium Lidding Foil Certificate of Analysis for aluminium lidding foil	5
A104592	Description of the Container/Closure System for bulk tablets	
Annexure 1	Brief description of outer container and pack size.	
<b>3.2.P.8</b>	<b>STABILITY</b>	<b>5</b>
<b>3.2.P.8.1</b>	<b>Stability Summary and Conclusion</b>	<b>5</b>

**1.1 COMPREHENSIVE TABLE OF CONTENTS**

---

U10-1457-01	Stability Summary and Conclusions Aspirin Film-coated Tablets, 5 mg	5
<b>3.2.P.8.2</b>	<b>Post-approval Stability Protocol and Stability Commitment</b>	<b>5</b>
H021085	Post-Approval Stability Protocol and Stability Commitment Aspirin Film-coated Tablets, 5 mg	
<b>3.2.P.8.3</b>	<b>Stability Data</b>	<b>5</b>
U10-1490-01	Stress Stability Data Aspirin Film-coated Tablets	5
U10-1422-01	Accelerated and Long-Term Stability Data Aspirin Film-coated Tablets, 5 mg	5
<b>3.3</b>	<b>LITERATURE REFERENCES</b>	<b>5</b>